摘要
背景:日常生活工具活动(IADL)是一种复杂的活动,涉及多种认知过程,容易受到认知的早期影响。损伤。以线人为基础的问卷是评估痴呆患者IADL表现的最常用工具,但在早期损伤阶段必须加以调整。 目的:探讨认知功能减退(无认知下降-主观认知功能减退-轻度认知功能损害-轻度痴呆-中度认知功能衰退)在认知功能障碍(IADL)上的差异。痴呆症)使用西班牙版的阿姆斯特丹IADL问卷(A-IADL-Q)。 方法:包括500名志愿者:88名无认知减退症状的参与者,109名主观认知投诉的参与者,114名轻度认知功能减退的参与者。轻度痴呆81例,中度痴呆108例。评估IADL的方法是A-IADL-Q,这是一份计算机化的自适应问卷,计算的是核心根据每个参与者的具体反应模式。资料采用ANOVAS和回归分析。用多项Logistic回归分析评价ca。A-IADL-Q的频域区分诊断组. 结果:无认知下降和主观认知功能下降的受试者A-IADL-Q得分高于MCI组,MCI组高于MCI组。痴呆症患者。A-IADL-Q对非认知障碍和痴呆有很好的鉴别能力,对非认知功能障碍和MCI的区分程度显著但低。 结论:α-IADL-Q能在不同痴呆谱组间鉴别IADL的功能.
关键词: 日常生活工具活动、阿姆斯特丹IADL问卷、日常活动、主观认知能力下降、轻度认知障碍、痴呆、多项Logistic回归分析。
Current Alzheimer Research
Title:Assessing Everyday Activities Across the Dementia Spectrum with the Amsterdam IADL Questionnaire
Volume: 15 Issue: 13
关键词: 日常生活工具活动、阿姆斯特丹IADL问卷、日常活动、主观认知能力下降、轻度认知障碍、痴呆、多项Logistic回归分析。
摘要: Background: Instrumental activities of daily living (IADL) are complex activities which involve multiple cognitive processes, and which are expected to be susceptible to the early effects of cognitive impairment. Informant-based questionnaires are the most common tools used to assess IADL performance in dementia, but must be adjusted for use in early stages of impairment.
Objective: To investigate the differences in IADL on the continuum of cognitive decline (i.e. no cognitive decline - subjective cognitive decline - mild cognitive impairment- mild dementia - moderate dementia) using the Spanish version of the Amsterdam IADL Questionnaire (A-IADL-Q).
Methods: A total of 500 volunteer participants were included: 88 participants with no signs of cognitive decline, 109 participants with subjective cognitive complaints, 114 participants with mild cognitive impairment (MCI), 81 participants with mild dementia and 108 participants with moderate dementia. IADL was assessed with the A-IADL-Q, a computerized and adaptive questionnaire that calculates scores according to the specific pattern of responses of each participant. The data were examined by ANOVAs and regression analysis. Multinomial logistic regression analysis was used to evaluate the capacity of the A-IADL-Q to distinguish between diagnostic groups.
Results: Participants with no cognitive decline and those with subjective cognitive decline obtained higher A-IADL-Q scores than MCI participants, and participants with MCI obtained higher scores than patients with dementia. The A-IADL-Q showed excellent discrimination between non-cognitive impairment and dementia, and significant but low discrimination between non-cognitive impairment and MCI.
Conclusion: A-IADL-Q can discriminate IADL functioning between groups across the dementia spectrum.
Export Options
About this article
Cite this article as:
Assessing Everyday Activities Across the Dementia Spectrum with the Amsterdam IADL Questionnaire, Current Alzheimer Research 2018; 15 (13) . https://dx.doi.org/10.2174/1567205015666180925113411
DOI https://dx.doi.org/10.2174/1567205015666180925113411 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Beta-Amyloid, Oxidative Stress and Down Syndrome
Current Alzheimer Research Application of NMR Spectroscopy in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry Hypersexuality As a Neuropsychiatric Disorder: The Neurobiology and Treatment Options
Current Drug Targets Impact of Natural Dietary Agents on Multiple Myeloma Prevention and Treatment: Molecular Insights and Potential for Clinical Translation
Current Medicinal Chemistry Natural Proteinaceous Inhibitors of Serine Proteases
Current Pharmaceutical Design The Implications of Autophagy in Alzheimer’s Disease
Current Alzheimer Research Metformin: Repurposing Opportunities for Cognitive and Mood Dysfunction
CNS & Neurological Disorders - Drug Targets AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models
Current Alzheimer Research Treatment of Alzheimer's Disease: Classical Therapeutic Approach
Current Pharmaceutical Analysis Peroxisome Proliferator-Activated Receptor-α Activation Protects Brain Capillary Endothelial Cells from Oxygen-Glucose Deprivation-Induced Hyperpermeability in the Blood-Brain Barrier
Current Neurovascular Research Cerebral Aneurysm Formation in Nitric Oxide Synthase-3 Knockout Mice
Current Neurovascular Research Targeting PPARalpha in Alzheimer's Disease
Current Alzheimer Research Editorial [ Drug Discovery for Alzheimers Disease: Filling the Pipeline Guest Editors: Antony R. Horton and Howard M. Fillit ]
Current Alzheimer Research <i>Thespesia populnea</i>: An Ethnomedicinal, Phytochemical and Pharmacological Review
The Natural Products Journal Recent Topics on Pharmacotherapy for Amphetamine-Type Stimulants Abuse and Dependence
Current Drug Abuse Reviews Anti-inflammatory strategies in stroke: a potential therapeutic target
Current Vascular Pharmacology Role of Wnt Signaling in the Control of Adult Hippocampal Functioning in Health and Disease: Therapeutic Implications
Current Neuropharmacology An Automatic Telemonitoring System for Elderly People at Home
International Journal of Sensors, Wireless Communications and Control Membrane Interactions of Oligomeric Alpha-Synuclein: Potential Role in Parkinsons Disease
Current Protein & Peptide Science Impaired Cognitive Function is Associated with Motor Function and Activities of Daily Living in Mild to Moderate Alzheimer's Dementia
Current Alzheimer Research